Physician profile
Mark Gold
NPI 1376953224
$4,390.36
in general payments reported to CMS, 2019-2025
22 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $92.07 · 2021: $598 · 2022: $629 · 2023: $646 · 2024: $894 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,823.71 | 2019-2025 | Clareon, Total30, Precision 1 |
| Abbvie INC. | $451.00 | 2022-2025 | |
| Sight Sciences, INC. | $399.15 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $306.40 | 2023-2025 | |
| Glaukos Corporation | $247.05 | 2019-2025 | Photrexa Viscous and Photrexa, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Dompe US, INC. | $210.93 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $205.42 | 2022-2024 | Xiidra, Stellaris |
| Ocular Therapeutix, INC. | $150.69 | 2021-2024 | Dextenza |
| Omeros Corporation | $113.91 | 2019-2021 | |
| Oyster Point Pharma, INC. | $113.88 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $71.29 | 2020-2022 | |
| New World Medical,INC. | $60.24 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Amgen INC. | $37.83 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $33.62 | 2025 | Xdemvy |
| Harrow Eye, LLC | $29.43 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $26.92 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $19.78 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.58 | 2021 | |
| Ivantis, INC | $19.41 | 2020 | |
| Thea Pharma INC. | $19.12 | 2024 | Iyuzeh |
| Rayner Intraocular Lenses Limited | $18.50 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.